Save Americans from the Fentanyl Emergency Act or the SAFE Act This bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Fentanyl-related substances are currently regulated under schedule I through a temporary order issued by the Drug Enforcement Administration. The temporary order expires on March 31, 2025. It limits mandatory minimum penalties for certain offenses involving fentanyl-related substances, establishes a process to deschedule or remove certain fentanyl-related substances that have a low potential for abuse, and allows federal courts to vacate or reduce sentences for convictions involving a fentanyl-related substance that is descheduled or moved to a schedule other than schedule I or II. The bill establishes a new, alternative registration process for schedule I research. It also makes other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. Finally, the bill requires the Government Accountability Office to analyze the implementation and impact of permanently placing fentanyl-related substances into schedule I of the Controlled Substances Act.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill introduced
Lobbying filed by BRISTOL-MYERS SQUIBB COMPANY
Lobbying filed by SANOFI US SERVICES INC
Lobbying filed by GSK (FKA GLAXOSMITHKLINE INC.)
Lobbying filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| SANOFI US SERVICES INC. | SANOFI US SERVICES INC | $2.5M | Apr 21, 2025 | 2025Q1 | MANHCRMMM |
| SANOFI US SERVICES INC. | SANOFI US SERVICES INC | $1.1M | Jul 21, 2025 | 2025Q2 | HCRMMMTRD |
| BRISTOL-MYERS SQUIBB COMPANY |
The lobbying table lists Senate LDA quarterly reports (LD-2) that cite this bill by number and cover a quarter of the 119th Congress. An LD-2 names a bill as “H.R. 1234” with no Congress, so a report on another Congress, which can only concern a different bill with the same number, is left out, even when it was filed after this Congress began. The amount is what the registrant reported for the whole filing, across every issue on it, not spending on this bill. Official actions and the bill summary come from Congress.gov, and votes from the roll-call record. This page no longer pairs the bill with members' stock trades: matching lobbying clients to traded companies by name, and trades to a bill by date, is not something the records establish.
Lobbying filed by SANOFI US SERVICES INC
| BRISTOL-MYERS SQUIBB COMPANY |
| $870.0K |
| Apr 20, 2025 |
| 2025Q1 |
HCRMMMTAX |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $800.0K | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| AEGIS LLC | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $60.0K | Jul 18, 2025 | 2025Q2 | PHAHCR |
| AEGIS LLC | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $60.0K | Apr 4, 2025 | 2025Q1 | PHAHCR |